EA201592012A1 - APPLICATION OF FLAGELLIN FOR IMPROVED CHEMOTHERAPY - Google Patents

APPLICATION OF FLAGELLIN FOR IMPROVED CHEMOTHERAPY

Info

Publication number
EA201592012A1
EA201592012A1 EA201592012A EA201592012A EA201592012A1 EA 201592012 A1 EA201592012 A1 EA 201592012A1 EA 201592012 A EA201592012 A EA 201592012A EA 201592012 A EA201592012 A EA 201592012A EA 201592012 A1 EA201592012 A1 EA 201592012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flagellin
application
improved chemotherapy
chemotherapy
relates
Prior art date
Application number
EA201592012A
Other languages
Russian (ru)
Other versions
EA201592012A8 (en
Inventor
Андрей ГУДКОВ
Людмила Г. Бурделя
Original Assignee
Кливлэнд Биолабс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кливлэнд Биолабс, Инк. filed Critical Кливлэнд Биолабс, Инк.
Publication of EA201592012A1 publication Critical patent/EA201592012A1/en
Publication of EA201592012A8 publication Critical patent/EA201592012A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Настоящее изобретение относится к способам и композициям, которые можно применять для лечения различных заболеваний, в том числе рака. Настоящее изобретение относится, в частности, к комбинированным терапевтическим стратегиям улучшения эффективности химиотерапии.The present invention relates to methods and compositions that can be used to treat various diseases, including cancer. The present invention relates in particular to combined therapeutic strategies for improving the effectiveness of chemotherapy.

EA201592012A 2014-02-21 2015-02-20 APPLICATION OF FLAGELLIN FOR IMPROVED CHEMOTHERAPY EA201592012A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942927P 2014-02-21 2014-02-21
PCT/US2015/016850 WO2015127227A1 (en) 2014-02-21 2015-02-20 Uses of flagellin for improved chemotherapy

Publications (2)

Publication Number Publication Date
EA201592012A1 true EA201592012A1 (en) 2017-02-28
EA201592012A8 EA201592012A8 (en) 2018-10-31

Family

ID=53879029

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592012A EA201592012A8 (en) 2014-02-21 2015-02-20 APPLICATION OF FLAGELLIN FOR IMPROVED CHEMOTHERAPY

Country Status (2)

Country Link
EA (1) EA201592012A8 (en)
WO (1) WO2015127227A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110420317B (en) * 2019-07-25 2022-11-22 中国人民解放军军事科学院军事医学研究院 Application of CBLB502 protein in preventing and treating posttraumatic stress disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
US20090124557A1 (en) * 2007-04-16 2009-05-14 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer
WO2009102818A1 (en) * 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides

Also Published As

Publication number Publication date
WO2015127227A1 (en) 2015-08-27
EA201592012A8 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201790737A1 (en) COMBINED THERAPY
MX2020003702A (en) Cyclopropylamines as lsd1 inhibitors.
MX2018008052A (en) Lsd1 inhibitors.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
EA201992251A1 (en) ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION
EA201691940A1 (en) NEW CONNECTIONS
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
MX2016007801A (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors.
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201691481A1 (en) C5a inhibitors for the treatment of viral pneumonia
EA201692529A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS USING FOLLYSTATINE POLYPEPTIDES
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
EA201890810A1 (en) COMPOUNDS EFFECTIVE FOR THE TREATMENT OF HEPATOTOXICITY AND LIVER STEATOSIS AND THEIR APPLICATION
MX2019013808A (en) Compounds for treatment of cancer.
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
EA201690039A1 (en) RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION
EA201791174A1 (en) ANTIMICOTIC CONNECTION
EA201891347A1 (en) Aza-benzimidazole inhibitors PAD4
EA201791814A1 (en) IMIDAZOLYL TRYCYCLIC ENONS AS ANTIOXIDANT INFLAMMATION MODULATORS